Natixis Advisors
GMAB icon

Natixis Advisors’s Genmab GMAB Stock Holding History

Natixis Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Sell
62,632
-8,348
-12% -$222K ﹤0.01% 1296
2026
Q1 		$1.9M Sell
70,980
-12,141
-15% -$364K ﹤0.01% 1126
2025
Q4 		$2.56M Sell
83,121
-110,828
-57% -$3.45M ﹤0.01% 983
2025
Q3 		$5.95M Buy
193,949
+63,504
+49% +$1.55M 0.01% 792
2025
Q2 		$2.69M Buy
130,445
+1,920
+1% +$39.4K ﹤0.01% 1009
2025
Q1 		$2.52M Sell
128,525
-77,244
-38% -$1.62M ﹤0.01% 1004
2024
Q4 		$4.29M Sell
205,769
-794
-0.4% -$17.4K 0.01% 857
2024
Q3 		$5.04M Buy
206,563
+47,437
+30% +$1.27M 0.01% 828
2024
Q2 		$4M Sell
159,126
-76,848
-33% -$2.18M 0.01% 856
2024
Q1 		$7.06M Buy
235,974
+48,176
+26% +$1.42M 0.02% 706
2023
Q4 		$5.98M Sell
187,798
-41,099
-18% -$1.29M 0.02% 704
2023
Q3 		$8.07M Buy
228,897
+64,085
+39% +$2.44M 0.02% 568
2023
Q2 		$6.26M Sell
164,812
-12,585
-7% -$502K 0.02% 651
2023
Q1 		$6.7M Sell
177,397
-22,910
-11% -$881K 0.02% 610
2022
Q4 		$8.49M Sell
200,307
-36,907
-16% -$1.52M 0.03% 525
2022
Q3 		$7.62M Buy
237,214
+109,103
+85% +$3.83M 0.03% 504
2022
Q2 		$4.16M Sell
128,111
-25,371
-17% -$822K 0.02% 703
2022
Q1 		$5.55M Buy
153,482
+8,810
+6% +$302K 0.02% 650
2021
Q4 		$5.72M Sell
144,672
-65
-0% -$2.71K 0.02% 623
2021
Q3 		$6.33M Sell
144,737
-15,171
-9% -$681K 0.03% 562
2021
Q2 		$6.53M Buy
159,908
+34,095
+27% +$1.32M 0.03% 546
2021
Q1 		$4.13M Sell
125,813
-8,890
-7% -$334K 0.02% 653
2020
Q4 		$5.48M Buy
134,703
+2,100
+2% +$78.5K 0.03% 518
2020
Q3 		$4.86M Sell
132,603
-26,074
-16% -$943K 0.03% 530
2020
Q2 		$5.38M Sell
158,677
-179,779
-53% -$4.9M 0.04% 482
2020
Q1 		$7.17M Buy
338,456
+53,225
+19% +$1.19M 0.06% 347
2019
Q4 		$6.37M Buy
285,231
+6,300
+2% +$137K 0.04% 447
2019
Q3 		$5.65M Buy
+278,931
New +$5.49M 0.04% 440

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Natixis Advisors's GMAB Position: Q2 2026 in Review

Natixis Advisors reduced its Genmab (GMAB) stake by 12% in Q2 2026, selling an estimated $222K and leaving 62,632 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1296.

Natixis Advisors first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $8.49M in Q4 2022. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Natixis Advisors held 62,632 shares of Genmab worth $1.72M as of Q2 2026.
  • Natixis Advisors sold 8,348 Genmab shares in Q2 2026, an estimated $222K.
  • Genmab made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1296 holding.
  • Natixis Advisors first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • Natixis Advisors's Genmab position peaked at $8.49M in Q4 2022.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.